The effect of pirfenidone on disease progression in asbestosis patients: a real-world Dutch cohort study

Findings based on asbestosis patients treated between 2004 and 2024 reveal a modest reduction in the rate of FVC decline (mean (95% CI) difference 7.0 (-5.8-19.7) mL·month(-1), p=0.22) and D (LCO) decline (0.11% (-0.19-0.41%), p=0.30) after starting pirfenidone https://bit.ly/45fZ5TR.